Marinomed Biotech AG
Vienna Stock Exchange MARI.VI
Marinomed Biotech AG Market Capitalization on January 14, 2025: USD 22.86 M
-
Marinomed Biotech AG 52-week high Market Capitalization is USD 52.56 M on January 15, 2024, which is 129.91% above the current Market Capitalization.
-
Marinomed Biotech AG 52-week low Market Capitalization is USD 8.29 M on August 22, 2024, which is -63.76% below the current Market Capitalization.
-
Marinomed Biotech AG average Market Capitalization for the last 52 weeks is USD 24.37 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Mr. Andreas Grassauer Ph.D. |
| IPO Date | Feb. 1, 2019 |
| Location | Austria |
| Headquarters | Hovengasse 25 |
| Employees | 36 |
| Sector | Health Care |
| Industries | |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email